Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.
Two posters from the American Society of Clinical Oncology Annual Meeting examined Medicare reimbursement trends for both originator and biosimilar biologics,1 as well as the use of a combination therapy incorporating a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma (HCC).2
In the first study, oncology biosimilars effectively drove down health care costs and drug reimbursement rates by breaking the upward price trend of reference agents, with the authors highlighting that more research needs to investigate the impact of rebates, payer policies, 340B programs, and discounts on average sales price (ASP) and Medicare reimbursement.
CMS used ASP as a benchmark for determining Medicare drug reimbursement (MCR) in the US, updating it quarterly. The study examined the trends in ASP and MCR reimbursement rates for 7 reference agents (rituximab, bevacizumab, trastuzumab, pegfilgrastim, filgrastim, infliximab, and epoetin alfa) and their 25 biosimilars over a 2-year period before and 5 years after the launch of the biosimilars.
The study utilized publicly available CMS data to compare the MCR trends of the reference products and their biosimilars. Results showed that, on average, the MCR for all reference agents increased by 9.2% in the 2 years before the launch of biosimilars. However, in the 5 years following the introduction of biosimilars, the MCR for reference agents decreased by 32.7%, while the MCR for biosimilars dropped by 50.3%. Additionally, biosimilar MCR rates declined more rapidly than those of reference agents.
Notably, 76% of biosimilars entered the market with an MCR lower than their reference agents, while 20% had a higher MCR. Subsequent biosimilars for reference agents typically launched with a higher MCR than the first biosimilar. Despite the overall decrease in MCR, reference agents still had rates double those of their corresponding biosimilars in the most recent quarter, except for pegfilgrastim, which experienced an 87% drop in MCR, resulting in a price lower than 5 out of its 6 biosimilars. This is likely due to Amgen, the company behind reference pegfilgrastim, prioritizing sales for its on-body pegfilgrastim device (Neulasta Onpro) over the original reference agent.3
The other study concluded that the combination of SCT-I10A, an anti-PD-1 monoclonal antibody, and SCT510, a bevacizumab biosimilar, offered significant clinical benefits compared with sorafenib and has an acceptable safety profile, supporting its use as a first-line treatment option for advanced HCC.
HCC is a major health issue in China and a leading cause of cancer-related deaths. The preferred initial therapy for advanced HCC involves combining immunotherapy with anti-vascular growth therapy. This study aimed to assess the safety and efficacy of SCT-I10A combined with SCT510 (a bevacizumab biosimilar) compared with sorafenib for first-line treatment of advanced HCC.
During the open-label, multicenter, phase 3 trial (NCT04560894) in China, patients with advanced HCC who had not previously received systemic therapy were enrolled. They were randomized to receive either SCT-I10A (200 mg every 3 weeks) plus SCT510 (15 mg/kg every 3 weeks) or sorafenib (400 mg orally twice daily). The primary end points were overall survival (OS) and progression-free survival.
By the interim analysis cutoff date of November 2, 2023, a total of 346 patients were enrolled and received at least 1 dose of the study drug (n = 230 in the SCT-I10A/SCT510 group; n = 116 in the sorafenib group), with a median follow-up of 19.7 months. The SCT-I10A/SCT510 group showed a significantly longer median OS (22.1 months) compared to the sorafenib group (14.2 months), with a hazard ratio (HR) of 0.60 (95% CI, 0.44-0.81; P = .0008).
Median PFS was also significantly longer in the SCT-I10A/SCT510 group (7.1 months) vs the sorafenib group (2.9 months; HR, 0.50; 95% CI, 0.38-0.65; P < .0001). The objective response rate was higher in the SCT-I10A plus SCT510 group (32.8%) compared to the sorafenib group (4.3%).
Grade 3 or higher treatment-related adverse events (TRAEs) were more common in the SCT-I10A/SCT510 group than in the sorafenib group (42.6% vs 33.6%), with hypertension being the most common grade 3 or higher TRAE (7.8% in the SCT-I10A/SCT510 group vs 4.3% in the sorafenib group). Three drug-related deaths occurred in the SCT510 group due to unknown causes, intracranial hemorrhage, or upper gastrointestinal hemorrhage.
References
1. Albaugh J, Indurlal P. Medicare reimbursement trends of biological agents and their biosimilars. Presented at: ASCO; May 31-June 4, 2024; Chicago, IL. Abstract 11155.
2. Xu J, Zhang Y, Wang G. SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial. Presented at: ASCO; May 31-June 4, 2024; Chicago, IL. Abstract 4092.
3. Bangia I. Contributor: Drug delivery devices help originator companies retain market share. The Center for Biosimilars®. September 19, 2020. Accessed June 19, 2024. https://www.centerforbiosimilars.com/view/contributor-drug-delivery-devices-help-originator-companies-retain-market-share
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment
December 9th 2024The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.